MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
MiMedx Group (MDXG) Reports Q4 Loss of $0.17/sh
March 8, 2021 5:36 PM ESTMiMedx Group (NASDAQ: MDXG) reported Q4 EPS of ($0.17), versus ($0.07) reported last year. Revenue for the quarter came in at $68.55 million, versus $76.4 million reported last year.
Outlook for 2021:
The Company expects adjusted net sales will increase 10% or more in 2021 over the prior year, assuming MiMedx is able to sell its micronized, particulate, and umbilical cord products for the full year. However, the United States Food and Drug Administration ("FDA") may determine that the Company's micronized, particulate, and/or umbilical... More
